Increased expression of BCL-2 and BCL-XL has been observed in NSCLC cell lines and specimens from patients [80,81]; these proteins participate in drug resistance resulting from the suppression of apoptosis induction by mitochondrial dysfunction [82,83,84]. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.